A Randomized, Double-blind, Placebo-controlled, Multi-centre, Sequential Design, Phase IIa Study to Evaluate Safety and Tolerability of Epicardial Injections of AZD8601 During Coronary Artery Bypass Grafting Surgery
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs AZD 8601 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors AstraZeneca
- 08 Jan 2018 According to a Moderna Therapeutics media release, dosing of patients is anticipated for early in the first quarter of 2018.
- 06 Dec 2017 Status changed from planning to not yet recruiting.
- 21 Sep 2017 New trial record